
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

April 25, 2007

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-50614
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

13700 Progress Boulevard
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:-

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD.

Oragenics, Inc. (the "Company") Common Stock is quoted on the American Stock Exchange (the "AMEX") under the symbol "ONI." In order for the Company's Common Stock to continue to be quoted on the AMEX, the Company must satisfy various continued listing standards as set forth in Part 10 of the AMEX Company Guide (the "AMEX Guide").

On April 25, 2007, the Company received notice from the AMEX that a review of the Company's Form 10-KSB for the year ended December 31, 2006 indicated that it did not meet certain of the AMEX's continued listing standards, and the Company has, therefore, become subject to the procedures and requirements of Section 1009 of the AMEX Guide. Specifically, the Company is not in compliance with Section 1003(a)(i) of the AMEX Guide with shareholders' equity of less than \$2,000,000 and losses from continuing operations and/or net losses in two of its most recent fiscal years.

In order to maintain its AMEX listing, the Company must submit a plan by May 25, 2007 advising AMEX of action it has taken, or will take that would bring it into compliance with all of the continued listing standards by October 27, 2008 (the "Plan"). The Company expects to submit a plan by May 25, 2007. Upon receipt of the Plan, AMEX will evaluate the Plan and make a determination as to whether the Company has made a reasonable demonstration in the Plan of an ability to regain compliance with the continued listing standards. If the Plan is accepted, the Company may be able to continue its listing during the specified timeframes but it will be subject to periodic review to determine whether it is making progress consistent with the plan.

There can be no assurance AMEX will accept the Company's Plan for continued listing. If the Plan is not accepted, the Company will be subject to delisting proceedings.

Item 9.01 Financial Information and Exhibits.**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated April 27, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

April 27, 2007

ORAGENICS, INC.
(Registrant)

BY: /s/ Robert T. Zahradnik

Robert T. Zahradnik

President and Chief Executive Officer

ORAGENICS, INC. RECEIVES NOTIFICATION LETTER FROM AMERICAN STOCK EXCHANGE

FOR IMMEDIATE RELEASE

ALACHUA, FL (April 27, 2007) –Oragenics, Inc. (AMEX: “ONI”) today reported it received notice from the American Stock Exchange (AMEX) advising the Company that it does not meet certain of the continued listing standards as set forth in part 10 of the AMEX Company Guide.

The biopharmaceutical development company said AMEX cited Section 1003(a)(i) of the AMEX Company Guide in that the Company had stockholders’ equity of less than \$2,000,000 and losses from continuing operations and/or net losses in two of its three most recent fiscal years. As of December 31, 2006, the Company reported stockholders’ equity of \$1,278,274.

In order to maintain its listing, the company intends to submit a plan to Amex within the 30 days permitted by AMEX that will outline Oragenics, Inc. strategy to bring itself back into compliance by October 27, 2008. If the Company’s plan to regain compliance is accepted by AMEX, the Company may be able to continue its listing during the 18-month period, during which time it will be subject to periodic review to determine progress consistent with the plan.

“We are exploring all of our options in order to maintain our listing on AMEX, and we hope to resolve this issue as quickly as possible,” said Robert T. Zahradnik, president and chief executive officer of Oragenics, Inc. “We expect future developments to help us return to compliance, but there can be no assurance that such expected future developments will result in our plan being accepted by AMEX, will materialize or occur in time, or if they do materialize, they will result in our returning to compliance.”

In addition, as a result of the Company’s continued need for additional funds, Oragenics reported that its independent registered certified public accounting firm has issued an unqualified audit report with an explanatory paragraph as to the Company’s ability to continue as a going concern. Oragenics continues to explore various strategic, financial and business alternatives available to it with the goal of sustaining anticipated operations and maximizing shareholder value. Additional information regarding Oragenics’ operations, growth plan, and liquidity and capital resources is set forth in the Company’s annual report on Form 10-KSB which was filed on March 23, 2007.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics’ core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.pl for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to fund our future operations and successfully develop and commercialize products using the iviGene proprietary technologies and those set forth in our most recently filed annual report on Form 10-KSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Robert T. Zahradnik, 386-418-4018 X222
www.oragenics.com